Evergreen Theragnostics Begins Construction of Manufacturing Facility

September 24, 2020

The radiopharmaceutical CDMO is building a new cGMP facility in Springfield, NJ.

Evergreen Theragnostics, a radiopharmaceutical contract development and manufacturing organization (CDMO) formed in 2019, began construction of a manufacturing facility in Springfield, NJ, the company announced in a Sept. 23, 2020 press release.

The new 14,000-ft2 facility, which is expected to open in 2021, is designed to meet global current good manufacturing practice standards for radiopharmaceutical manufacturing, including therapeutic and centrally distributed diagnostic radiopharmaceuticals. The facility will have four fully equipped production suites, three additional customizable suites, research space, multiple sterility lines, quality control, material storage, and packaging space. 

The company plans to support preclinical and early-stage clinical trials and full-scale commercial manufacturing of approved products. The facility location was chosen for its proximity to transportation hubs and the pharmaceutical talent pool in the area.

"We are excited to take one more step forward in realizing our goal of providing high quality and high reliability manufacturing of radiopharmaceuticals in North America. We are encouraged to see companies in our industry developing so many exciting new drugs and are eager to provide a top-tier manufacturing service to support their efforts," said James Cook, CEO of Evergreen, in the press release.

Source: Evergreen